Abstract:
Objective
To investigate the availability of entecavir and hepatitis B virus immunoglobulin(HBIG)on the immunoprophylaxis of the HBV recurrence after orthotopic liver transplantation(OLT)with high risks of HBV reinfection.
Methods
Two-way cohort study was adopted in our trial.38 patients,who underwent liver transplantation in our center from March 2006 to June 2007,were followed up prospectively with the combination of intramuscular hepatitis B virus immunoglobulin and entecavir.116 patients,who underwent liver transplantation from September 2003 to March 2006,were analyzed retrospectively with the combination of intramuscular hepatitis B virus immunoglobulin and Lamivudine as the prophylaxis for HBV reinfection.HBV markers in serum,HBV DNA,the cumulative recurrence were analyzed.
Results
Entecavir group,in the follow-up period of （18.5±5.3）months,had been traced no HBV recurrence.However,15 petients had been traced for (18.93±8.56)months in lamivudine group.The rate of HBV recurrence in entecavir group was lower than in lamivudine group(0 vs 12.93%, P＜0.05). The cumulative recurrence of entecavir group was lower than that of Lamivuding group.
Conclusion
Combination ofentecavir and intramuscular HBIG as the prophylaxis of HBV reinfection is more effective than the lamivudine and intramuscular HBIG group,especially to the patients with the high risks of HBV recurrence.
Key words:
Livetransplantation,
Hepatitis Bvirus,
Nucleoside analogue,
Immunoglobulin
Chang-jie CAI, Hui ZHAO, Yi GUO, Yu-ling AN, Min-qiang LU, Gui-hua CHEN. Clinical trial of entecavir as prophylaxis of HBV reinfection after liver transplantation[J]. Chinese Archives of General Surgery(Electronic Edition), 2008, 02(05): 385-389.